ReviewChinese medicine2025
The role and therapeutic advances of neutrophils in acute myocardial infarction: from traditional chinese medicine modulation to modern therapeutic strategies.
Review in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Acute Myocardial Infarction (AMI) is one of the leading causes of global mortality, posing a severe threat to human health. Currently, the clinical management of AMI remains a major challenge, and its pathological mechanisms lack systematic elucidation. Neutrophils, as key effector cells in the pathogenesis of AMI, have emerged as a highly promising therapeutic target. This review comprehensively summarizes the origin, subtypes, stage-specific roles, and mechanistic contributions of neutrophils in AMI. Furthermore, it explores how active components of traditional Chinese medicine (TCM) modulate neutrophil function through multi-target interventions, exerting therapeutic effects in anti-inflammation, anti-fibrosis, and pro-angiogenesis. Recent advances highlight significant progress in neutrophil-targeted therapies, including novel drug development, nanoparticle-based delivery systems, and multi-omics biomarker discovery, offering new avenues for precision medicine in AMI. Although translational challenges persist, enhanced collaboration between basic research and clinical applications may unlock innovative treatment strategies for AMI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.